FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.2  |  FHIR Version n/a  User: [n/a]

425638005: Recombinant hepatitis B virus surface antigen 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/acellular pertussis 25micrograms injection solution 0.5mL prefilled syringe (product)


    Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2020. Module: SNOMED CT core

    Descriptions:

    Id Description Lang Type Status Case? Module
    2662929015 Recombinant hepatitis B virus surface antigen 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/acellular pertussis 25micrograms injection solution 0.5mL prefilled syringe (product) en Fully specified name Active Only initial character case insensitive (core metadata concept) SNOMED CT core
    2674862010 Recombinant hepatitis B virus surface antigen 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/acellular pertussis 25micrograms injection solution 0.5mL prefilled syringe en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
    4731341000005119 rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml da Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) Danish module (core metadata concept)


    0 descendants.

    Expanded Value Set


    Outbound Relationships Type Target Active Characteristic Refinability Group Values
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml Is a difteri- + tetanus- + kighoste- + rekombinant hepatitis B-virus-vaccine false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. rekombinant vaccine mod hepatitis B-virus false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. difterivaccine false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. kighostevaccine false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. tetanustoxoid false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml Has manufactured dose form injektionsvæske false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. Diphtheria toxoid false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. tetanusvaccine false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. Diphtheria vaccine false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml Is a Product manufactured as parenteral dose form (product) false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml Has manufactured dose form Solution for injection false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml Is a TEMPORARY parent for CDs that are not updated false Inferred relationship Some
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. kighostevaccine false Inferred relationship Some 3
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. tetanusvaccine false Inferred relationship Some 4
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. Diphtheria vaccine false Inferred relationship Some 2
    rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. rekombinant vaccine mod hepatitis B-virus false Inferred relationship Some 1

    Inbound Relationships Type Active Source Characteristic Refinability Group

    Reference Sets

    Concept inactivation indicator reference set

    POSSIBLY EQUIVALENT TO association reference set (foundation metadata concept)

    Back to Start